Cardio-oncology: the Nuclear Option

go back to reference DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71. doi:10.3322/caac.21235.CrossRefPubMed DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71. doi:10.​3322/​caac.​21235.CrossRefPubMed

go back to reference Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077–84. doi:10.1056/NEJM200004133421502.CrossRefPubMed Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077–84. doi:10.​1056/​NEJM200004133421​502.CrossRefPubMed

go back to reference •• Russell RR, Alexander J, Jain D, Poornima IG, Srivastava AV, Storozynsky E, et al. The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. J Nucl Cardiol. 2016;23(4):856–84. doi:10.1007/s12350-016-0538-8. This informational statement provides a useful summary of many of the currently used chemotherapeutic agents and their associated cardiovascular toxicities. In addition, it provides a comparison of all of the recommended monitoring protocols for anthracyclines and trastuzumab.CrossRefPubMed •• Russell RR, Alexander J, Jain D, Poornima IG, Srivastava AV, Storozynsky E, et al. The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. J Nucl Cardiol. 2016;23(4):856–84. doi:10.​1007/​s12350-016-0538-8. This informational statement provides a useful summary of many of the currently used chemotherapeutic agents and their associated cardiovascular toxicities. In addition, it provides a comparison of all of the recommended monitoring protocols for anthracyclines and trastuzumab.CrossRefPubMed

go back to reference Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25(25):3991–4008. doi:10.1200/JCO.2007.10.9777.CrossRefPubMed Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25(25):3991–4008. doi:10.​1200/​JCO.​2007.​10.​9777.CrossRefPubMed

go back to reference Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–21.CrossRefPubMed Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–21.CrossRefPubMed

go back to reference Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979;300(6):278–83. doi:10.1056/NEJM197902083000603.CrossRefPubMed Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979;300(6):278–83. doi:10.​1056/​NEJM197902083000​603.CrossRefPubMed

go back to reference •• Schwartz RG, McKenzie WB, Alexander J, Sager P, D’Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy : Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82(6):1109–18. The first published recommendations for monitoring LVEF in patients receiving anthracyclines. Demonstrated a significant decrease in the development of clinical heart failure in patients whose management was congruent with the recommendations.CrossRefPubMed •• Schwartz RG, McKenzie WB, Alexander J, Sager P, D’Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy : Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82(6):1109–18. The first published recommendations for monitoring LVEF in patients receiving anthracyclines. Demonstrated a significant decrease in the development of clinical heart failure in patients whose management was congruent with the recommendations.CrossRefPubMed

go back to reference Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol. 2003;10(2):132–9. doi:10.1067/mnc.2003.7.CrossRefPubMed Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol. 2003;10(2):132–9. doi:10.​1067/​mnc.​2003.​7.CrossRefPubMed

go back to reference Mor-Avi V, Lang RM. Is echocardiography reliable for monitoring the adverse cardiac effects of chemotherapy? J Am Coll Cardiol. 2013;61(1):85–7. doi:10.1016/j.jacc.2012.10.006.CrossRefPubMed Mor-Avi V, Lang RM. Is echocardiography reliable for monitoring the adverse cardiac effects of chemotherapy? J Am Coll Cardiol. 2013;61(1):85–7. doi:10.​1016/​j.​jacc.​2012.​10.​006.CrossRefPubMed

go back to reference •• Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61(1):77–84. doi:10.1016/j.jacc.2012.09.035. This study demonstrated the importance of utilizing noncontrast 3D transthoracic echocardiography to other echocardiographic modalities in assessing patients for cardiotoxicity because of the low variability of the method.CrossRefPubMed •• Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61(1):77–84. doi:10.​1016/​j.​jacc.​2012.​09.​035. This study demonstrated the importance of utilizing noncontrast 3D transthoracic echocardiography to other echocardiographic modalities in assessing patients for cardiotoxicity because of the low variability of the method.CrossRefPubMed

go back to reference Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911–39. doi:10.1016/j.echo.2014.07.012.CrossRefPubMed Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911–39. doi:10.​1016/​j.​echo.​2014.​07.​012.CrossRefPubMed

go back to reference Hendel RC, Patel MR, Kramer CM, Poon M, Hendel RC, Carr JC, et al. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol. 2006;48(7):1475–97. doi:10.1016/j.jacc.2006.07.003.CrossRefPubMed Hendel RC, Patel MR, Kramer CM, Poon M, Hendel RC, Carr JC, et al. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol. 2006;48(7):1475–97. doi:10.​1016/​j.​jacc.​2006.​07.​003.CrossRefPubMed

go back to reference •• Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 2012;23 Suppl 7:vii155–66. doi:10.1093/annonc/mds293. The ESMO guidelines provide up-to-date protocols for monitoring cardiotoxicity for anthracyclines and trastuzumab that include the use of biomarkers in monitoring.CrossRefPubMed •• Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 2012;23 Suppl 7:vii155–66. doi:10.​1093/​annonc/​mds293. The ESMO guidelines provide up-to-date protocols for monitoring cardiotoxicity for anthracyclines and trastuzumab that include the use of biomarkers in monitoring.CrossRefPubMed

go back to reference Gerber TC, Gibbons RJ. Weighing the risks and benefits of cardiac imaging with ionizing radiation. JACC Cardiovasc Imaging. 2010;3(5):528–35. doi:10.1016/j.jcmg.2010.03.003.CrossRefPubMed Gerber TC, Gibbons RJ. Weighing the risks and benefits of cardiac imaging with ionizing radiation. JACC Cardiovasc Imaging. 2010;3(5):528–35. doi:10.​1016/​j.​jcmg.​2010.​03.​003.CrossRefPubMed

go back to reference Mackey JR, Clemons M, Cote MA, Delgado D, Dent S, Paterson A, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol. 2008;15(1):24–35.CrossRefPubMedPubMedCentral Mackey JR, Clemons M, Cote MA, Delgado D, Dent S, Paterson A, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol. 2008;15(1):24–35.CrossRefPubMedPubMedCentral

go back to reference Panjrath GS, Jain D. Trastuzumab-induced cardiac dysfunction. Nucl Med Commun. 2007;28(2):69–73. doi:10.1097/MNM.0b013e328025ae04.CrossRefPubMed Panjrath GS, Jain D. Trastuzumab-induced cardiac dysfunction. Nucl Med Commun. 2007;28(2):69–73. doi:10.​1097/​MNM.​0b013e328025ae04​.CrossRefPubMed

go back to reference Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13(5):699–709. doi:10.1093/annonc/mdf132.CrossRefPubMed Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13(5):699–709. doi:10.​1093/​annonc/​mdf132.CrossRefPubMed

go back to reference Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258–62. doi:10.1016/j.jacc.2006.07.052.CrossRefPubMed Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258–62. doi:10.​1016/​j.​jacc.​2006.​07.​052.CrossRefPubMed

go back to reference •• Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355–62. doi:10.1016/j.jacc.2013.02.072. This study demonstrated the cardioprotective effects of the combination of ACE inhibitor and beta-blocker in patients receiving anthracyclines.CrossRefPubMed •• Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355–62. doi:10.​1016/​j.​jacc.​2013.​02.​072. This study demonstrated the cardioprotective effects of the combination of ACE inhibitor and beta-blocker in patients receiving anthracyclines.CrossRefPubMed

go back to reference Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213–20. doi:10.1016/j.jacc.2009.03.095.CrossRefPubMed Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213–20. doi:10.​1016/​j.​jacc.​2009.​03.​095.CrossRefPubMed

go back to reference Lestuzzi C, Vaccher E, Talamini R, Lleshi A, Meneguzzo N, Viel E, et al. Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. Ann Oncol. 2014;25(5):1059–64. doi:10.1093/annonc/mdu055.CrossRefPubMed Lestuzzi C, Vaccher E, Talamini R, Lleshi A, Meneguzzo N, Viel E, et al. Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. Ann Oncol. 2014;25(5):1059–64. doi:10.​1093/​annonc/​mdu055.CrossRefPubMed

go back to reference Abou El Fadl MH, Bagai RK, Spiro TP, Daw HA. 5-Fluorouracil-induced cardiotoxicity during chemotherapy for adenocarcinoma of the small bowel. Gastrointest Cancer Res. 2009;3(4):167–70.PubMedPubMedCentral Abou El Fadl MH, Bagai RK, Spiro TP, Daw HA. 5-Fluorouracil-induced cardiotoxicity during chemotherapy for adenocarcinoma of the small bowel. Gastrointest Cancer Res. 2009;3(4):167–70.PubMedPubMedCentral

go back to reference National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Hodgkins Lymphoma Version 3. 2016. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Hodgkins Lymphoma Version 3. 2016.

go back to reference Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics. 2008;121(2):e387–96. doi:10.1542/peds.2007-0575.CrossRefPubMed Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics. 2008;121(2):e387–96. doi:10.​1542/​peds.​2007-0575.CrossRefPubMed

go back to reference Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov. 2011;10(2):111–26. doi:10.1038/nrd3252.CrossRefPubMed Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov. 2011;10(2):111–26. doi:10.​1038/​nrd3252.CrossRefPubMed

go back to reference •• Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596–603. doi:10.1161/CIRCIMAGING.112.973321. This study demonstrated the utility of assessing global longitudinal strain in monitoring for cardiotoxicity.CrossRefPubMedPubMedCentral •• Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596–603. doi:10.​1161/​CIRCIMAGING.​112.​973321. This study demonstrated the utility of assessing global longitudinal strain in monitoring for cardiotoxicity.CrossRefPubMedPubMedCentral

go back to reference Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639–42. doi:10.1038/nm.2919.CrossRefPubMed Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639–42. doi:10.​1038/​nm.​2919.CrossRefPubMed

go back to reference Bennink RJ, van den Hoff MJ, van Hemert FJ, de Bruin KM, Spijkerboer AL, Vanderheyden JL, et al. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med. 2004;45(5):842–8.PubMed Bennink RJ, van den Hoff MJ, van Hemert FJ, de Bruin KM, Spijkerboer AL, Vanderheyden JL, et al. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med. 2004;45(5):842–8.PubMed

go back to reference Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol. 2004;37(4):837–46.CrossRefPubMed Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol. 2004;37(4):837–46.CrossRefPubMed

go back to reference Gabrielson KL, Mok GS, Nimmagadda S, Bedja D, Pin S, Tsao A, et al. Detection of dose response in chronic doxorubicin-mediated cell death with cardiac technetium 99m annexin V single-photon emission computed tomography. Mol Imaging. 2008;7(3):132–8.PubMedPubMedCentral Gabrielson KL, Mok GS, Nimmagadda S, Bedja D, Pin S, Tsao A, et al. Detection of dose response in chronic doxorubicin-mediated cell death with cardiac technetium 99m annexin V single-photon emission computed tomography. Mol Imaging. 2008;7(3):132–8.PubMedPubMedCentral

go back to reference Narula J, Acio ER, Narula N, Samuels LE, Fyfe B, Wood D, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med. 2001;7(12):1347–52.CrossRefPubMed Narula J, Acio ER, Narula N, Samuels LE, Fyfe B, Wood D, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med. 2001;7(12):1347–52.CrossRefPubMed

go back to reference Su H, Gorodny N, Gomez LF, Gangadharmath U, Mu F, Chen G, et al. Noninvasive molecular imaging of apoptosis in a mouse model of anthracycline-induced cardiotoxicity. Circ Cardiovasc Imaging. 2015;8(2), e001952. doi:10.1161/CIRCIMAGING.114.001952.CrossRefPubMedPubMedCentral Su H, Gorodny N, Gomez LF, Gangadharmath U, Mu F, Chen G, et al. Noninvasive molecular imaging of apoptosis in a mouse model of anthracycline-induced cardiotoxicity. Circ Cardiovasc Imaging. 2015;8(2), e001952. doi:10.​1161/​CIRCIMAGING.​114.​001952.CrossRefPubMedPubMedCentral

go back to reference Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol. 2001;37(1):4–9. doi:10.1002/mpo.1155.CrossRefPubMed Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol. 2001;37(1):4–9. doi:10.​1002/​mpo.​1155.CrossRefPubMed

go back to reference Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002;13(5):710–5.CrossRefPubMed Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002;13(5):710–5.CrossRefPubMed

go back to reference Carrio I, Estorch M, Berna L, Germa JR, Alonso C, Ojeda B, et al. Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies. Eur J Nucl Med. 1991;18(10):806–12.CrossRefPubMed Carrio I, Estorch M, Berna L, Germa JR, Alonso C, Ojeda B, et al. Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies. Eur J Nucl Med. 1991;18(10):806–12.CrossRefPubMed

go back to reference Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism. 2002;51(3):314–7.CrossRefPubMed Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism. 2002;51(3):314–7.CrossRefPubMed

go back to reference Estorch M, Carrio I, Berna L, Martinez-Duncker C, Alonso C, Germa JR, et al. Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med. 1990;31(12):1965–9.PubMed Estorch M, Carrio I, Berna L, Martinez-Duncker C, Alonso C, Germa JR, et al. Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med. 1990;31(12):1965–9.PubMed

go back to reference Carrio I, Estorch M, Berna L, Lopez-Pousa J, Tabernero J, Torres G. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med. 1995;36(11):2044–9.PubMed Carrio I, Estorch M, Berna L, Lopez-Pousa J, Tabernero J, Torres G. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med. 1995;36(11):2044–9.PubMed

go back to reference Carrio I. Cardiac neurotransmission imaging. J Nucl Med. 2001;42(7):1062–76.PubMed Carrio I. Cardiac neurotransmission imaging. J Nucl Med. 2001;42(7):1062–76.PubMed

go back to reference Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55(20):2212–21. doi:10.1016/j.jacc.2010.01.014.CrossRefPubMed Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55(20):2212–21. doi:10.​1016/​j.​jacc.​2010.​01.​014.CrossRefPubMed

go back to reference Valdes Olmos RA, ten Bokkel Huinink WW, Greve JC, Hoefnagel CA. I-123 MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity. Clin Nucl Med. 1992;17(3):163–7.CrossRefPubMed Valdes Olmos RA, ten Bokkel Huinink WW, Greve JC, Hoefnagel CA. I-123 MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity. Clin Nucl Med. 1992;17(3):163–7.CrossRefPubMed

go back to reference Takano H, Ozawa H, Kobayashi I, Hamaoka S, Nakajima A, Nakamura T, et al. Atrophic nerve fibers in regions of reduced MIBG uptake in doxorubicin cardiomyopathy. J Nucl Med. 1995;36(11):2060–1.PubMed Takano H, Ozawa H, Kobayashi I, Hamaoka S, Nakajima A, Nakamura T, et al. Atrophic nerve fibers in regions of reduced MIBG uptake in doxorubicin cardiomyopathy. J Nucl Med. 1995;36(11):2060–1.PubMed

go back to reference Wakasugi S, Fischman AJ, Babich JW, Aretz HT, Callahan RJ, Nakaki M, et al. Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med. 1993;34(8):1283–6.PubMed Wakasugi S, Fischman AJ, Babich JW, Aretz HT, Callahan RJ, Nakaki M, et al. Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med. 1993;34(8):1283–6.PubMed

go back to reference Valdes Olmos RA, ten Bokkel Huinink WW, ten Hoeve RF, van Tinteren H, Bruning PF, van Vlies B, et al. Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy. Eur J Cancer. 1995;31A(1):26–31.CrossRefPubMed Valdes Olmos RA, ten Bokkel Huinink WW, ten Hoeve RF, van Tinteren H, Bruning PF, van Vlies B, et al. Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy. Eur J Cancer. 1995;31A(1):26–31.CrossRefPubMed

go back to reference Nousiainen T, Vanninen E, Jantunen E, Remes J, Kuikka J, Hartikainen J. Anthracycline-induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake. Clin Physiol. 2001;21(1):123–8.CrossRefPubMed Nousiainen T, Vanninen E, Jantunen E, Remes J, Kuikka J, Hartikainen J. Anthracycline-induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake. Clin Physiol. 2001;21(1):123–8.CrossRefPubMed

go back to reference Saito K, Takeda K, Imanaka-Yoshida K, Imai H, Sekine T, Kamikura Y. Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: comparative study with myocardial perfusion, left ventricular function, and histopathological findings. Ann Nucl Med. 2003;17(6):481–8.CrossRefPubMed Saito K, Takeda K, Imanaka-Yoshida K, Imai H, Sekine T, Kamikura Y. Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: comparative study with myocardial perfusion, left ventricular function, and histopathological findings. Ann Nucl Med. 2003;17(6):481–8.CrossRefPubMed

go back to reference Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1(2), e000364. doi:10.1161/JAHA.111.000364.CrossRefPubMedPubMedCentral Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1(2), e000364. doi:10.​1161/​JAHA.​111.​000364.CrossRefPubMedPubMedCentral

go back to reference Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12. doi:10.1161/circulationaha.116.021612.CrossRefPubMed Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12. doi:10.​1161/​circulationaha.​116.​021612.CrossRefPubMed

go back to reference Merlini G, Narula J, Arbustini E. Molecular imaging of misfolded protein pathology for early clues to involvement of the heart. Eur J Nucl Med Mol Imaging. 2014;41(9):1649–51. doi:10.1007/s00259-014-2832-5.CrossRefPubMed Merlini G, Narula J, Arbustini E. Molecular imaging of misfolded protein pathology for early clues to involvement of the heart. Eur J Nucl Med Mol Imaging. 2014;41(9):1649–51. doi:10.​1007/​s00259-014-2832-5.CrossRefPubMed

go back to reference Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjo L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54(2):213–20. doi:10.2967/jnumed.111.102053.CrossRefPubMed Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjo L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54(2):213–20. doi:10.​2967/​jnumed.​111.​102053.CrossRefPubMed

go back to reference Dorbala S, Vangala D, Semer J, Strader C, Bruyere Jr JR, Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41(9):1652–62. doi:10.1007/s00259-014-2787-6.CrossRefPubMed Dorbala S, Vangala D, Semer J, Strader C, Bruyere Jr JR, Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41(9):1652–62. doi:10.​1007/​s00259-014-2787-6.CrossRefPubMed